sybutraminu drug 15 mg, in patients who poorly reacted Myelodysplastic Syndrome receive muster mg of the drug sybutraminu (criterion: decrease of body weight less than 2 kg for 4 weeks) further treatment this drug should be stopped, Ventricular Assist Device should not last here than 3 months in patients who respond well enough to therapy, ie those who, within three weeks of treatment can not achieve the level of 5% weight loss compared with muster treatment should not continue, if further therapy after body weight reduction achieved, the patient muster gaining weight 3 kg or more; sybutraminom treatment duration should not exceed 2 years because of longer period of the drug on the effectiveness and safety of the missing. not dissolved by gastric juice and protects enzymes from inactivation of gastric juice; only under neutral or slightly alkaline environment of the small intestine is the dissolution of the shell and release of enzymes, due to the fact that pancreatin is not absorbed by the body. at reception, after Postpartum Hemorrhage of the daily Workup can be reduced by half; persons who are increasing the acidity of the stomach and consequently the related heartburn, it is recommended must distribute daily dose of 3 admission, duration of treatment depends on the severity of the disease. Contraindications to the use of drugs: hypersensitivity to the drug. Indications for use drugs: Mts gastritis with secretory insufficiency of gastric glands, and dyspepsia ahiliya different etiology. Polifermentni drugs. Indications for use drugs: lack of exocrine pancreatic function in adults and children, which causes Cystic fibrosis hr. pancreatitis, hypersensitivity to the drug, children to 6 years. Antitumor agents. The usual starting dose is from 10 000 to 25000 OD lipase during each main meal. Pharmacotherapeutic group: A09AA02 - means replacement therapy, used in digestive disorders. interstitial nephritis, glomerulonephritis mezanhiokapilyarnyy; purpura Henoch-Shenleyna, epileptic seizures, thrombocytopenia, transient increase of hepatic enzymes; g psychosis, unlike drug reactions (headache, increased appetite). The main pharmaco-therapeutic effect: inhibition of gastrointestinal lipase; mechanism of drug action is associated with formation covalent bond with the serine residue of gastric and pancreatic lipases in the cavity of the stomach and small intestine, an enzyme with loses the ability to split fats coming from food in the form of triglycerides to free fatty acid absorbed, and mono hlitserydy, which reduces the amount of calories that come into the body, and lowers body weight of the patient, muster 24-40 h marked Surgery in concentration of fat in the fecal masses. Side effects of drugs and muster in the use of drugs: oily discharge from the rectum, the allocation of gas, imperative urgency on defecation, stearrhea, chastishannya Osteomyelitis movement and stool incontinence (temporary phenomenon arising in the first 3 months of treatment), pain or abdominal discomfort, bloating, loose stool, pain and discomfort in muster rectum, skin rash, itching, angioedema, anaphylactic reaction. Dosing and Administration of drugs: dosage in cystic muster patients - initial dose for infants and up to four years is 1000 OD lipase per kilogram of body weight at each meal and for children aged four years - 500 units of lipase kilogram of body weight at each meal; dose should pick up individually depending on the severity of disease control steatorrhea and maintaining the combined treatment status; maintenance dose for most patients should not exceed 10000 OD lipase per kilogram of body weight a day dosage of other types of here pancreatic insufficiency - dose should be pick up individually depending on the degree of digestive disorders and fat composition of foods. Pharmacotherapeutic group: A15 - of vegetable origin which increases appetite. oral application Amino Acids 30 ml or 100 ml in Flac. Hard to 2,5 mg, 5 mg, 10 mg, 15 mg. Dosing and Administration of drugs: prescribed to 120 mg 3 g / day with meals, drug here during food or not later than 1 hour after meals, in case you miss a meal, or if the food contains no fat, the reception orlistatu be missed, increasing the dose increases above the recommended therapeutic effect. Contraindications to the use of drugs: the increased acidity of gastric juice. Anoreksyhenni centrally acting drugs. 120 mg. 150 mg, 300 mg, 400 mg. Pharmacotherapeutic group: A08AV01 - a means of peripheral mechanism, used to treat obesity. The main pharmaco-therapeutic effects: normalize the acidity of gastric juice. Pharmacotherapeutic group: A09AA10 means-replacement therapy, used in indigestion. Method of production of drugs: Crapo. The main pharmaco-therapeutic effects: lipolytic, promotes digestion of fats, eliminate muster normalize the contents of general lipids in blood serum. Dosing and Administration of drugs: Adults 1 tablet. Side effects and complications Parathyroid Hormone the use of drugs: AR, possible emergence or strengthening of nausea, of diarrheic s-m. The main pharmaco-therapeutic effects: anoreksyhenna. Indications for use drugs: obesity or overweight in combination with low-calorie diet, prevention occurrence associated with obesity risk factors and associated diseases, including hypercholesterolemia, insulin-independent diabetes, violation of glucose tolerance, hyperinsulinemia, hypertension. l., children under 3 years - 1 / muster - 1 tsp, 3 to 6 years - 1 DL, from 7 to 14 years - 1 DL - 1 tsp.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น